FDA Approves Tysabri To Treat Moderate-To-Severe Crohn's Disease (Medical News Today)
The U.S. Food and Drug Administration has approved Tysabri (natalizumab) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies.

Monday's Health Winners & Losers (TheStreet.com)
Biogen Idec climbs on FDA approval.